about
Say No to DMSO: Dimethylsulfoxide Inactivates Cisplatin, Carboplatin, and Other Platinum ComplexesEffect of a monofunctional phenanthriplatin-DNA adduct on RNA polymerase II transcriptional fidelity and translesion synthesisThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsPhotocytotoxic trans-diam(m)ine platinum(IV) diazido complexes more potent than their cis isomers.Organometallic Titanocene-Gold Compounds as Potential Chemotherapeutics in Renal Cancer. Study of their Protein Kinase Inhibitory Properties.The Fanconi anemia pathway and ICL repair: implications for cancer therapy.Axial ligand exchange of N-heterocyclic cobalt(III) Schiff base complexes: molecular structure and NMR solution dynamics.Rational design of [Co(acacen)L2]+ inhibitors of protein functionRetained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin.Luminescent iminophosphorane gold, palladium and platinum complexes as potential anticancer agents.Inhibition of transcription by platinum antitumor compoundsPotential anticancer heterometallic Fe-Au and Fe-Pd agents: initial mechanistic insights.Synthetic methods for the preparation of platinum anticancer complexes.Zinc finger proteins as templates for metal ion exchange and ligand reactivity. Chemical and biological consequences.Pt-based drugs: the spotlight will be on proteins.Platinum-based drugs: past, present and future.The induction of lysis in lysogenic strains of Escherichia coli by a new antitumor transplatin derivative and its DNA interactions.trans-Platinum(II) complex of 3-aminoflavone - synthesis, X-ray crystal structure and biological activities in vitro.Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex.Cytotoxic gold compounds: synthesis, biological characterization and investigation of their inhibition properties of the zinc finger protein PARP-1.Modulation of drug activation profiles through carboxylate ligand modification in cytotoxic trans-platinum planar amine compounds.A tetrazolato-bridged dinuclear platinum(II) complex exhibits markedly high in vivo antitumor activity against pancreatic cancer.Platinum-based drugs and proteins: reactivity and relevance to DNA adduct formation.Non-traditional platinum compounds for improved accumulation, oral bioavailability, and tumor targeting.Geometry matters: inverse cytotoxic relationship for cis/trans-Ru(ii) polypyridyl complexes from cis/trans-[PtCl2(NH3)2]Copper binding modulates the platination of human copper chaperone Atox1 by antitumor trans-platinum complexes.The RING heterodimer BRCA1-BARD1 is a ubiquitin ligase inactivated by the platinum-based anticancer drugs.Biological evaluation of transdichloridoplatinum(II) complexes with 3- and 4-acetylpyridine in comparison to cisplatin.Deciphering of interactions between platinated DNA and HMGB1 by hydrogen/deuterium exchange mass spectrometry.Using phosphine ligands with a biological role to modulate reactivity in novel platinum complexes.Anticancer potential of a photoactivated transplatin derivative containing the methylazaindole ligand mediated by ROS generation and DNA cleavage.Synthesis of platinum(II) complexes of 2-cycloalkyl-substituted benzimidazoles and their cytotoxic effects.Internalization of Ineffective Platinum Complex in Nanocapsules Renders It Cytotoxic.Platinum and Palladium Polyamine Complexes as Anticancer Agents: The Structural FactorMultivariant Crystallization of Tetraplatin Precursors from Solutions Containing 1,2-C6H10(NH3)2 2+ and [PtCl6]2– Ions
P2860
Q24289008-698002C4-1A72-4B55-831E-DE63188CCD4EQ24613748-59FF29CF-5464-4097-A02E-95B12279F914Q28066801-E02D0770-9A7F-4C60-9048-B791C63D80D9Q34105902-E9C73483-E582-4CDB-91A6-9564AE578A46Q34576153-A985054D-BAF0-4926-8175-D32E6014D0C7Q35024542-6CC0DE20-40DF-4381-AA28-4A894B795D9BQ36560196-F6F299F3-C5F6-4101-9696-77472D8B9568Q36635722-77F02254-D0DE-47F0-B083-BC815C9E52A8Q36920272-407CAF74-C4CA-4ED4-983A-D4A1D32B8672Q37269801-631F0206-D352-4E06-B5F2-71E36F7EEC1AQ37364815-550CA0AF-1386-4FF1-BCDD-D8CDAD0E3808Q37432620-50FE31E7-9F87-40D0-AC11-B09D3093114FQ37722632-F4E95FCA-6D45-4CAC-8849-AC34A9CFF0A7Q37831171-6950DAAE-D043-4EBD-88EE-B66372C44379Q38186602-D93564E4-6120-45CA-9A33-419C9614FD4DQ38737115-6A860770-14F0-4C4C-AFC3-E8C66858034CQ38939537-5E7E9555-011C-4EF1-B945-BEFE1720A535Q38967226-7785F740-EBD1-46C8-A862-6EF749F6BBAEQ39155790-69F9D833-5BD1-4848-B0FB-D52FE3BC0794Q39404168-3A7A110C-DDD4-4283-B337-052D0EEB874CQ39473654-EE459861-AF2E-480B-B9E0-F88E7A348752Q39557153-6FAA1544-9BE4-4035-854E-7E97D809D760Q41784926-D45C1AF3-65AF-425E-9A3C-D890E7731310Q42155449-08F8C202-7664-44FB-8FFD-D4DC9169ECAEQ42161331-B8F8AED8-4573-41BF-95F4-4077ADE0DC67Q42707142-4DB94106-F3ED-4751-B56A-37440BD63975Q42874055-9472DC03-79D7-4BBD-88B1-93317C6C74C6Q42925820-8C91219C-AB8F-4AA0-B9D5-D6AC385FF1C2Q51045898-996A50D2-B9C2-496C-B8F5-14BBB045C42FQ52363628-A3AECC7C-2DEB-4919-8754-5F08A060D50CQ52860409-CF3F6823-4001-44BA-99E6-97C9CEC21BF3Q53467177-F605592C-01E1-4EAF-8F6F-7E043C0E20A8Q53800846-082288A1-B113-4DEC-9B32-E34962D8058CQ58993871-5B308051-E314-4EF4-B6BA-5ECF99408ECFQ59145819-EE5B902E-B023-4AD9-9A81-0706A234DF73
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Towards Antitumor Active trans-Platinum Compounds.
@ast
Towards Antitumor Active trans-Platinum Compounds.
@en
type
label
Towards Antitumor Active trans-Platinum Compounds.
@ast
Towards Antitumor Active trans-Platinum Compounds.
@en
prefLabel
Towards Antitumor Active trans-Platinum Compounds.
@ast
Towards Antitumor Active trans-Platinum Compounds.
@en
P2860
P356
P1476
Towards Antitumor Active trans-Platinum Compounds.
@en
P2093
Nicholas P Farrell
Sheena M Aris
P2860
P356
10.1002/EJIC.200801118
P577
2009-04-01T00:00:00Z